{"id":4216,"date":"2026-11-05T09:00:00","date_gmt":"2026-11-05T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4216"},"modified":"2026-11-11T20:45:27","modified_gmt":"2026-11-12T00:45:27","slug":"fda-grants-rybrevant-faspro-accelerated-approval-in-hnscc","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4216","title":{"rendered":"FDA Grants Rybrevant Faspro Accelerated Approval in HNSCC"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Janssen_Rybrevant_Faspro_Therapeutic_Indications-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4234\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Janssen_Rybrevant_Faspro_Therapeutic_Indications-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Janssen_Rybrevant_Faspro_Therapeutic_Indications-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Janssen_Rybrevant_Faspro_Therapeutic_Indications-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Janssen_Rybrevant_Faspro_Therapeutic_Indications-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Janssen_Rybrevant_Faspro_Therapeutic_Indications.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Janssen Biotech (Johnson &amp; Johnson)<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>FDA accelerated approval<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>EGFR\/MET bispecific antibody (subcutaneous)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>EGFR; MET<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Recurrent or metastatic head and neck squamous cell carcinoma<\/p>\n<h4>Summary<\/h4>\n<p>Source-gap recovery: on November 5, 2026, the US FDA granted Janssen Biotech accelerated approval for subcutaneous amivantamab and hyaluronidase-lpuj as monotherapy after platinum chemotherapy and anti-PD-(L)1 therapy in specified recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). HPV-associated oropharyngeal carcinoma is excluded.<\/p>\n<p>The FDA reviewed the open-label, multicenter OrigAMI-4 primary efficacy population of 102 patients. Confirmed overall response rate was 42% (95% CI 32\u201352%); 56% of responders maintained response at least six months. The label rests on response and duration, with clinical benefit to be verified in the randomized OrigAMI-5 study. The FDA lists a projected confirmatory completion date of May 31, 2029. This November 5 action was recovered in the 14-day source-gap check.<\/p>\n<h4>Deep Analysis<\/h4>\n<p>Amivantamab binds EGFR and MET, signaling nodes relevant to HNSCC; hyaluronidase enables subcutaneous delivery. <strong>Interpretation A:<\/strong> a 42% confirmed response in a post-platinum, post-immunotherapy setting supports a meaningful new option for an underserved population. Support: FDA authorization, blinded response review and responses of at least six months in over half of responders. Against: single-arm comparison with historical therapy cannot establish a survival advantage, and the HPV-associated oropharyngeal exclusion narrows use.<\/p>\n<p><strong>Interpretation B:<\/strong> the response endpoint may not translate to sufficient survival or quality-of-life benefit after accounting for toxicity and treatment burden. Support: accelerated status requires verification; the label warns for administration reactions, pneumonitis, dermatologic and ocular toxicity. Against: depth and duration of tumor shrinkage justify access while confirmation runs. OrigAMI-5 overall survival, progression-free survival, patient-reported outcomes, exposure, discontinuation and real-world adverse events will upgrade or falsify durable clinical benefit. Biomarker-defined EGFR\/MET dependence and resistance deserve study.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>HNSCC is epithelial cancer of the head and neck with poor options after platinum chemotherapy and checkpoint blockade. Rybrevant Faspro combines the EGFR\/MET bispecific antibody amivantamab with hyaluronidase for subcutaneous administration. Janssen Biotech is a Johnson &amp; Johnson subsidiary.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Verified: FDA approval date and narrow indication, 102-patient efficacy set, 42% response, 56% six-month response persistence, required confirmatory trial.<\/li>\n<li>Missing: randomized survival benefit, population-level durability and real-world tolerability.<\/li>\n<li>Independent corroboration: FDA approval notice, FDA label and company release.<\/li>\n<li>Falsifier: confirmatory randomized study fails to verify benefit.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>A high-importance regulatory expansion for a dual-target antibody. Direction is positive for access, while the magnitude of patient benefit beyond tumor response remains uncertain until the required randomized study reports.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 5 of 5. Signal Direction: positive for regulatory access; long-term clinical benefit uncertain. Confidence in Facts: high because FDA primary records confirm the action and outcomes. Confidence in Interpretation: moderate-low pending confirmatory data.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Source-gap recovery: on November 5, 2026, the US FDA granted Janssen Biotech accelerated approval for subcutaneous amivantamab and hyaluronidase-lpuj as monotherapy after platinum chemotherapy and anti-PD-(L)1 therapy in specified recurrent or metastatic head and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4234,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[753,234,1442],"class_list":["post-4216","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-amivantamab","tag-head-and-neck-squamous-cell-carcinoma","tag-janssen-biotech"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4216"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4216\/revisions"}],"predecessor-version":[{"id":4249,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4216\/revisions\/4249"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4234"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}